Search research articles
Contact Us
Filters
Showing results (31-40 of 188) with videos related to
Page
of 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2011
Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma
Hua Fang, Theresa M Harned, Ondrej Kalous, et al.
Journal of the National Cancer Institute
|
July 12, 2007
Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide
Nino Keshelava, Elai Davicioni, Zesheng Wan, et al.
Blood
|
May 16, 2002
Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis
Leonid S Metelitsa, Stephen D Gillies, Michael Super, et al.
Pediatric Blood & Cancer
|
October 30, 2013
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program
Raushan T Kurmasheva, C Patrick Reynolds, Min H Kang, et al.
Pediatric Blood & Cancer
|
October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing
Min H Kang, Malcolm A Smith, Christopher L Morton, et al.
Cancer Immunology, Immunotherapy : CII
|
February 26, 2015
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma
Diana Seidel, Anastasia Shibina, Nikolai Siebert, et al.
Molecular Cancer Therapeutics
|
October 14, 2003
Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines
Hiroaki Goto, Bo Yang, Denise Petersen, et al.
Cancer Research
|
June 18, 2003
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate
Yasuyoshi Sohara, Hiroyuki Shimada, Miriam Scadeng, et al.
Cancers
|
February 13, 2021
Neuroblastoma Invasion Strategies Are Regulated by the Extracellular Matrix
Cian Gavin, Nele Geerts, Brenton Cavanagh, et al.
Pediatric Blood & Cancer
|
September 19, 2017
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program
Raushan T Kurmasheva, Dias Kurmashev, C Patrick Reynolds, et al.
Page
of 19
Search research articles
Search
Showing results (31-40 of 188) with videos related to
Sort By:
Page
of 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2011
Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma
Hua Fang, Theresa M Harned, Ondrej Kalous, et al.
Journal of the National Cancer Institute
|
July 12, 2007
Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide
Nino Keshelava, Elai Davicioni, Zesheng Wan, et al.
Blood
|
May 16, 2002
Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis
Leonid S Metelitsa, Stephen D Gillies, Michael Super, et al.
Pediatric Blood & Cancer
|
October 30, 2013
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program
Raushan T Kurmasheva, C Patrick Reynolds, Min H Kang, et al.
Pediatric Blood & Cancer
|
October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing
Min H Kang, Malcolm A Smith, Christopher L Morton, et al.
Cancer Immunology, Immunotherapy : CII
|
February 26, 2015
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma
Diana Seidel, Anastasia Shibina, Nikolai Siebert, et al.
Molecular Cancer Therapeutics
|
October 14, 2003
Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines
Hiroaki Goto, Bo Yang, Denise Petersen, et al.
Cancer Research
|
June 18, 2003
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate
Yasuyoshi Sohara, Hiroyuki Shimada, Miriam Scadeng, et al.
Cancers
|
February 13, 2021
Neuroblastoma Invasion Strategies Are Regulated by the Extracellular Matrix
Cian Gavin, Nele Geerts, Brenton Cavanagh, et al.
Pediatric Blood & Cancer
|
September 19, 2017
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program
Raushan T Kurmasheva, Dias Kurmashev, C Patrick Reynolds, et al.
Page
of 19